ArticleJournal of the American Heart Association2024
Metabolic Signatures of Blood Pressure and Risk of Cardiovascular Diseases.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Molecular Diagnostic Approach for Hypertension Through Establishment of a Metabolite Risk Score Using a Multi-Metabolite Panel Identified via UHPLC-MS/MS.International journal of molecular sciences · 2026Article
- Metabolomic signatures connect and mediate sedentary time-driven mortality risk in patients with cardiovascular disease.Frontiers in sports and active living · 2026Article
- Sex-stratified metabolic signatures of adiposity indices and their associations with clinical biomarkers in the UK Biobank.EBioMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe underlying biological mechanisms linking blood pressure (BP) and cardiovascular diseases (CVD) are only partly understood. We aimed to identify metabolic signatures associated with systolic and diastolic BP and investigate their subsequent association with risk of CVD. METHODS AND
resultsThe study included 201 742 UK Biobank participants with measurements on 249 metabolic biomarkers. A multistep adaptive elastic net penalized regression with 10-fold cross-validation was employed to identify metabolic signatures for systolic BP and diastolic BP. External validation was conducted on 848 participants from the EHS (Epirus Health Study). We further assessed the associations between BP metabolic signatures and incident composite CVD (N=6742), myocardial infarction (N=4192), and stroke (N=2757) in the UK Biobank, using multivariable Cox regression models. The metabolic signatures comprised 31 and 25 metabolites, robustly correlated with systolic BP and diastolic BP, respectively, in both the UK Biobank and the EHS. Following adjustments (including BP), the metabolic signature for systolic BP was positively associated with incident myocardial infarction (hazard ratio [HR], 1.11 [95% CI, 1.07-1.15]) and CVD (HR, 1.07 [95% CI, 1.04-1.10]). Similarly, the metabolic signature for diastolic BP was associated with a higher risk of myocardial infarction (HR, 1.16 [95% CI, 1.12-1.20]) and CVD (HR, 1.09 [95% CI, 1.05-1.12]). The associations between the signatures and stroke were not significant. The metabolic signatures partly mediated the total effect of the BP traits on the risk of myocardial infarction and CVD.
conclusionsOur findings may enhance our understanding of the biological mechanisms through which BP affects CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.